Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NPCE 
Neuropace Inc (NPCE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/02/2025: NPCE (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $17.5
1 Year Target Price $17.5
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 164.01% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 521.27M USD | Price to earnings Ratio - | 1Y Target Price 17.5 |
Price to earnings Ratio - | 1Y Target Price 17.5 | ||
Volume (30-day avg) 8 | Beta 1.9 | 52 Weeks Range 7.56 - 18.98 | Updated Date 12/2/2025 |
52 Weeks Range 7.56 - 18.98 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.75 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-04 | When - | Estimate -0.1959 | Actual -0.11 |
Profitability
Profit Margin -25.29% | Operating Margin (TTM) -9.51% |
Management Effectiveness
Return on Assets (TTM) -11.19% | Return on Equity (TTM) -169.27% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 531433805 | Price to Sales(TTM) 5.49 |
Enterprise Value 531433805 | Price to Sales(TTM) 5.49 | ||
Enterprise Value to Revenue 5.86 | Enterprise Value to EBITDA -16.94 | Shares Outstanding 33307734 | Shares Floating 22091688 |
Shares Outstanding 33307734 | Shares Floating 22091688 | ||
Percent Insiders 2.73 | Percent Institutions 92.66 |
Upturn AI SWOT
Neuropace Inc
Company Overview
History and Background
NeuroPace, Inc. was founded in 1997. It is a commercial-stage medical device company focused on designing, developing, and marketing products for the treatment of neurological disorders. Their core technology is the RNS System, a closed-loop brain-responsive neurostimulation system.
Core Business Areas
- RNS System: The RNS System is NeuroPace's flagship product, a closed-loop brain-responsive neurostimulation system for treating refractory epilepsy. It monitors brain activity, detects unusual patterns associated with seizures, and delivers targeted electrical stimulation to prevent them.
Leadership and Structure
NeuroPace is led by a CEO and has a typical corporate structure with departments such as Research and Development, Sales and Marketing, Regulatory Affairs, and Operations. As of March 2024, Michael Favet is the Chief Executive Officer.
Top Products and Market Share
Key Offerings
- RNS System: The RNS System is the primary product. It's designed to treat refractory epilepsy. While precise market share data for brain-responsive neurostimulation is limited, NeuroPace is a key player in this niche market. Competitors for epilepsy treatment include companies offering alternative therapies such as VNS (Vagus Nerve Stimulation) from LivaNova (LIVN), deep brain stimulation (DBS) therapies, and pharmaceutical treatments. Revenue is primarily generated by sales of the RNS system and related services.
Market Dynamics
Industry Overview
The medical device industry, specifically the neuromodulation sector, is growing. Epilepsy treatment is a significant area of unmet need, driving demand for innovative solutions like the RNS System.
Positioning
NeuroPace is positioned as a leader in brain-responsive neurostimulation for epilepsy. Its competitive advantage lies in the closed-loop nature of the RNS System, which personalizes treatment based on real-time brain activity.
Total Addressable Market (TAM)
The estimated TAM for NeuroPace is difficult to precisely quantify but consists of the proportion of drug resistant epilepsy patients who do not respond to standard treatments. The TAM is in the multiple billions of USD. NeuroPace is strongly positioned to capture a significant portion of the TAM
Upturn SWOT Analysis
Strengths
- Innovative RNS System
- Personalized Treatment Approach
- Established Clinical Evidence
- Strong Intellectual Property Protection
Weaknesses
- Relatively High Cost of the RNS System
- Limited Market Penetration (niche market)
- Dependence on a Single Product
- Requires specialized surgical expertise for implantation
Opportunities
- Expanding Indications for the RNS System
- Increasing Awareness of Brain-Responsive Neurostimulation
- Partnerships with Research Institutions
- Geographic Expansion
- Technology can be applied to other neurological conditions
Threats
- Competition from Alternative Therapies
- Regulatory Changes
- Reimbursement Challenges
- Technological Advancements by Competitors
Competitors and Market Share
Key Competitors
- LIVN
- MDT
- ABT
Competitive Landscape
NeuroPace's advantage is its closed-loop technology. Disadvantages include its relatively high cost and limited market penetration compared to larger competitors offering broader neuromodulation solutions.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by increasing adoption of the RNS System and expansion of clinical evidence supporting its efficacy.
Future Projections: Future growth is expected to come from expanding indications, increasing market penetration, and potential partnerships.
Recent Initiatives: Recent initiatives may include clinical trials for new indications, marketing campaigns, and product enhancements.
Summary
NeuroPace is a company in a niche area, with an innovative product, but faces financial and adoption challenges. Their responsive RNS system offers personalized epilepsy treatment and has a technological advantage. Future growth hinges on expanding indications and market penetration. However, high costs, regulatory hurdles, and competition could pose risks and are issues the company has to look out for.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings, Market research reports, Analyst reports
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neuropace Inc
Exchange NASDAQ | Headquaters Mountain View, CA, United States | ||
IPO Launch date 2021-04-22 | CEO, President & Director Mr. Joel D. Becker | ||
Sector Healthcare | Industry Medical Devices | Full time employees 209 | Website https://www.neuropace.com |
Full time employees 209 | Website https://www.neuropace.com | ||
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet and patient data management system; and nSight Platform, which facilitates ongoing patient monitoring and streamlines patient support. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.